You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Go to Close Top

Dosage & device

Avamys once daily 1

  • Avamys is indicated for the treatment of the symptoms of allergic rhinitis in adults, adolescents and children (6 years and over) 1

Delivery system 2

Avamys device

How to use the Avamys device

Watch the video to find out more.

Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/UK/uk-how-to-use-avamys-device-video.mp4

Patient preference study

In a multicenter, randomized, double-blind, cross-over, patient preference study, that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis, 56% of patients preferred Avamys over MFNS (32%) 3 (n=300, p<0,001). The patient preferences of products may contribute to improved treatment adherence and enhanced treatment outcome in AR patients. 4

Overall, significantly more patients preferred FFNS over MFNS, p<0.001 3
56% FFNS

[n=155]

32% MFNS

[n=87]

Overall 5 patients (2%) reported AEs with FFNS and 13 patients (4%) with MFNS. Few common AEs were reported: rhinorrhoea, nasal discomfort, cough. No severe safety issues were identified during the study. 3

Avamys provided improved experience vs Nasonex 3

Running nose

Less run out of the nose /
less drip down the throat 3

(p<0.05 and p<0.001, respectively)

Less irritation

Less irritation 3

(p<0.001)

More soothing

More soothing 3

(p<0.05)

AE: Adverse event; AR: Allergic rhinitis; FFNS: Fluticasone furoate nasal spray; MFNS: Mometasone furoate nasal spray.

References:

  1. Avamys summary of product characteristics.
  2. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4(6):689-701.
  3. Yanez A, Dimitroff A, Bremner P, et al. A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis. Allergy Rhinol. 2016;7(4):e183–e192.
  4. Yonezaki M, Akiyama K, Karaki M, et al. Preference evaluation and perceived sensory comparison of fluticasone furoate and mometasone furoate intranasal sprays in allergic rhinitis. Auris Nasus Larynx. 2016;43(3):292-297.

Avamys is a registered trademark of the GlaxoSmithKline group of companies.